New Vaccine-Immunotherapy combo targets breast cancer brain metastases
NCT ID NCT04348747
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase IIa trial tests a combination of a dendritic cell vaccine (targeting HER2/HER3 proteins) and the immunotherapy drug pembrolizumab (Keytruda) in 23 women with breast cancer that has spread to the brain. The vaccine aims to train the immune system to attack cancer cells, while pembrolizumab helps unleash the immune response. The study is currently recruiting and will measure how well the treatment shrinks brain tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dendritic cell vaccine (targeting HER2/HER3) and pembrolizumab (Keytruda)
What this could lead to
If it works, this could point toward a new treatment option for breast cancer that has spread to the brain, potentially shrinking tumors and improving outcomes.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The combination therapy may cause side effects or fail to shrink brain metastases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE BRAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
ACTIVE_NOT_RECRUITINGTampa, Florida, 33612, United States
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Virginia Comprehensive Cancer Center
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact